ADTX - Aditxt, Inc.

0.4746
0.008   1.601%

Share volume: 93,690
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.72%

PREVIOUS CLOSE
CHG
CHG%
$0.47
0.01
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
35%
Profitability 35%
Dept financing 42%
Liquidity 13%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.23%
1 Month
-23.78%
3 Months
-84.59%
6 Months
-49.23%
1 Year
698.99%
2 Year
-86.12%
Key data
Stock price
$0.47
P/E Ratio 
0.00
DAY RANGE
$0.44 - $0.49
EPS 
-$672.16
52 WEEK RANGE
$0.02 - $12.92
52 WEEK CHANGE
$821.55
MARKET CAP 
3.724 M
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
$0.00
EX-DIVIDEND DATE
03-17-2025
NEXT EARNINGS DATE
05-19-2025
BETA 
0.24
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$126,670
AVERAGE 30 VOLUME 
$153,176
Company detail
CEO: Amro Albanna
Region: US
Website: aditxt.com
Employees: 60
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Aditxt, Inc. develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies.

Recent news